557 related articles for article (PubMed ID: 11376113)
1. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
2. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
4. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.
Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N
J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429
[TBL] [Abstract][Full Text] [Related]
5. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
6. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads.
Itoh F; Asao H; Sugamura K; Heldin CH; ten Dijke P; Itoh S
EMBO J; 2001 Aug; 20(15):4132-42. PubMed ID: 11483516
[TBL] [Abstract][Full Text] [Related]
7. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development.
Zhang D; Schwarz EM; Rosier RN; Zuscik MJ; Puzas JE; O'Keefe RJ
J Bone Miner Res; 2003 Sep; 18(9):1593-604. PubMed ID: 12968668
[TBL] [Abstract][Full Text] [Related]
8. The in vivo roles of müllerian-inhibiting substance.
Behringer RR
Curr Top Dev Biol; 1994; 29():171-87. PubMed ID: 7828438
[TBL] [Abstract][Full Text] [Related]
9. Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.
Wu X; Zhang N; Lee MM
Endocrinology; 2012 Oct; 153(10):4929-37. PubMed ID: 22872577
[TBL] [Abstract][Full Text] [Related]
10. BMP and activin receptor expression in lens development.
de Iongh RU; Chen Y; Kokkinos MI; McAvoy JW
Mol Vis; 2004 Aug; 10():566-76. PubMed ID: 15346106
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.
Fynn-Thompson E; Cheng H; Teixeira J
Mol Cell Endocrinol; 2003 Dec; 211(1-2):99-104. PubMed ID: 14656482
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.
Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL
J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228
[TBL] [Abstract][Full Text] [Related]
13. Components of the anti-Müllerian hormone signaling pathway in gonads.
di Clemente N; Josso N; Gouédard L; Belville C
Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470
[TBL] [Abstract][Full Text] [Related]
14. AMH signaling: from receptor to target gene.
Visser JA
Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478
[TBL] [Abstract][Full Text] [Related]
15. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
17. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
18. Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.
Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
Mol Cell Endocrinol; 2003 Dec; 211(1-2):15-9. PubMed ID: 14656471
[TBL] [Abstract][Full Text] [Related]
19. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
20. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter.
Ishida W; Hamamoto T; Kusanagi K; Yagi K; Kawabata M; Takehara K; Sampath TK; Kato M; Miyazono K
J Biol Chem; 2000 Mar; 275(9):6075-9. PubMed ID: 10692396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
